AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06664658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peep 5
Description: he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
Study NCT06664658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peep 10
Description: he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
Study NCT06664398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one HIIT
Description: one HIIT high intensity interval training
Study NCT06664398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: four HIIT
Description: four HIIT high intensity interval training
Study NCT05568394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy combinded with therapeutic exercise
Description: The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks).
Study NCT05568394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks).
Study NCT06612086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (Forxiga)
Description: we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
Study NCT06611436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 1
Study NCT06611436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 2
Study NCT06611436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 3
Study NCT06611436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
Study NCT04286347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HCV, HBV, HIV tests
Description: HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
Study NCT05584449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Attend online group facilitated by two oncology social workers
Study NCT05584449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Discuss survivorship issues/concerns
Study NCT05584449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive young adult cancer survivorship information
Study NCT05584449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT05584449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05584449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06369740 — intervention group
Intervention type: OTHER
Intervention: Case scenarios - questionnaire
Description: Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.
Study NCT06369740 — intervention group
Intervention type: OTHER
Intervention: Case scenarios - Focus groups
Description: Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.
Study NCT06369740 — intervention group
Intervention type: OTHER
Intervention: Use scenarios - Usability test
Description: Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).
Study NCT06369740 — intervention group
Intervention type: OTHER
Intervention: Use scenarios - interview
Description: The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
Study NCT04865822 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single session pain education class
Description: Pain education classes will be provided in person group or virtual settings
Study NCT05581368 — intervention group
Intervention type: OTHER
Intervention: Chronic Cannabis use
Description: The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
Study NCT06428097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.
Study NCT06428097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Study NCT05250609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrown composite.
Description: It is a type of restoration has been shown a great success in adult and recently has been suggested for children
Study NCT04931134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation - active
Description: Active trigeminal nerve stimulation
Study NCT04931134 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trigeminal nerve stimulation - sham
Description: Sham trigeminal nerve stimulation
Study NCT04726982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg once daily
Study NCT04726982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 500 mg once daily
Study NCT04726982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study NCT05226104 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MOXI
Description: Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
Study NCT04770805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
Study NCT05745740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Study NCT05745740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400 mg by oral once a day.
Study NCT05251233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.
Study NCT05251233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: The study will use commercial supply.
Study NCT04788732 — intervention group
Intervention type: DEVICE
Intervention: ECG and EEG monitoring
Description: the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
Study NCT05751135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration
Description: Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching of shortened lower extremity muscle
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching of shortened lower extremity muscle
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening
Description: Strengthening exercises for weak lower extremity muscles
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening exercises for weak lower extremity muscles
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning
Description: Positioning of participant to maintain a good body posture
Study NCT05751135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Positioning of participant to maintain a good body posture
Study NCT04895397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Nerve Block procedure
Description: In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane.
Study NCT05418387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support Network Intervention
Description: The navigator will provide basic patient navigation services and Supportive Health Education to the patient/caregiver dyads in the patient's preferred language using the Support Network Workbook. The intervention will consist of 7 telephone sessions. There will be 2 sessions in the first month and one session per month after the first month (6 months total). Coaching and guiding techniques rather than lectures will be used applying dyads' specific social support network information. Each session will be about 30 minutes long.
Study NCT05418387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (Patient Navigation Service)
Description: The patient navigator will provide basic patient navigation services consisting of health care barriers/social needs assessment, referral to social workers (if eligible) and support groups for patients and caregivers, and transportation assistance without Supportive Health Education. Patient/caregiver dyads in the control group will be contacted at 3- and 6-months post-enrollment and asked about their experience receiving treatment, any challenges they encountered or are currently facing, and the care support they received from family members, friends, CHWs, and health care providers.
Study NCT06425419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.
Study NCT06222723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered for 10 days. For the first 48 hours, dexamethasone will be given iv. After 48 hours, a switch to oral dexamethasone (same dosage) is permitted at the discretion of the study physician.
Study NCT06222723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
Study NCT06222723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin treatment will be administered iv for 10 days, as recommended in the Nigeria Centre for Disease Control and Prevention National Guidelines for LF Case Management.
Study NCT05083559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC AP algorithm
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal inputs. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure. The metabolic expenditure then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM.
Study NCT05083559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robust R-AP algorithm
Description: The R-AP is a modified MPC algorithm. A new feature in the algorithm includes a model for missed meal insulin detection. The model includes estimations for carbohydrate consumption based glucose patterns to determine if that person has consumed a meal without announcing it to the system.
Study NCT05925049 — intervention group
Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study NCT04904978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blanx Black Toothpaste
Description: Use of Blanx Black Toothpaste twice a day per at least 2 minutes.
Study NCT04904978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Sensation White
Description: Use of Colgate Sensation White Toothpaste twice a day per at least 2 minutes
Study NCT05945849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33KO-HSPC; CART33
Description: CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells.
Study NCT05153590 — intervention group
Intervention type: DRUG
Intervention: Saxenda®
Description: Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.
Study NCT05115955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS group
Description: In DS group, subjects will receive intramuscular single dose of NALDEBAIN® at least 12 hours before surgery.
Study NCT05115955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In Control group, subjects will receive intramuscular 2 ml sesame oil at least 12 hours before surgery.
Study NCT06228053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX-682
Description: Specified dose twice daily
Study NCT06228053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Specified dose once daily
Study NCT05580588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336
Description: 400 mg SPH4336 PO QD
Study NCT05197881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Ethos Adaptive Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study NCT05166512 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Cooks
Description: 6 'food agency' based cooking skills classes during the first 4 months of the DPP
Study NCT05166512 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP
Description: Standard DPP
Study NCT05558189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Coordinated Reset (vCR)
Description: The purpose of this study is to test the efficacy of vibrotactile coordinated reset stimulation on human subject participants who have refractory Parkinson's disease post surgical treatment
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT886
Description: PT886 monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47.
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy as a combination partner to PT886 in Part C: Cohort 1
Study NCT06213597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine swallowing rehabilitation
Description: Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
Study NCT06213597 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: routine swallowing rehabilitation
Description: Routine swallowing rehabilitation training mainly included oral and facial muscle training, ice stimulation therapy, Mendelssohn maneuver training, and tongue root resistance training. The subjects were treated twice a day, Monday through Saturday, for 20 min each time for 2 weeks. All operations were performed by the same trained and qualified professional rehabilitation therapist.
Study NCT06213597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real repetitive transcranial magnetic stimulation
Description: In the rTMS group, 5 Hz rTMS was applied to the hot spot of the supraglottic motor cortex of the affected hemisphere at a treatment intensity of 80% resting motor threshold for 10 min, with a total of 250 pulses (with an interval of 11 s for every 1 s of continuous stimulation), and the treatment was performed once a day for 6 d per week for 2 weeks.
Study NCT06213597 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation
Description: The sham rTMS group supplemented pseudomagnetic stimulation at the hotspot of the representative area, tilted the magnetic stimulation coil at 90°, and the same noise was emitted by the instrument during the treatment, but no stimulation was performed, and the group was treated once a day, 6d per week, for 2 weeks.
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy as a combination partner to Abraxane and PT886 in Part C: Cohort 2
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chemotherapy as a combination partner to Gemcitabine and PT886 in Part C: Cohort 2
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA® (pembrolizumab)
Description: Immune checkpoint inhibitor as a combination partner to PT886 in Part D: Cohort 3, 4, and 5.
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4
Study NCT05482893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Chemotherapy as a combination partner to KEYTRUDA® (pembrolizumab) and PT886 in Part D: Cohort 4